Notable
MONITOR · Adherence to Subcutaneous vs. Intravenous Vedolizumab · Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2027
Mercy Medical CenterNot specified NCT06750731 Registry history of NCT06750731 on ClinicalTrials.gov (opens the registry)
Updated